Therapeutic targeting of innate immunity in the failing heart

Journal of Molecular and Cellular Cardiology

Volumn 51, Issue 4, 2011, Pages 594-599

  Topkara, Veli K ^a   Evans, Sarah ^a   Zhang, Weili ^a   Epelman, Slava ^a   Staloch, Lora ^a   Barger, Philip M ^a   Mann, Douglas L ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cardiac remodeling; Damage associated molecular; Innate immunity; Patterns; Toll like receptors

Indexed keywords

AP 177; APTAMER; CD14 ANTIGEN; CPG 52364; ERITORAN; IBUDILAST; LIDID IVA; LIPID A DERIVATIVE; LIPOPOLYSACCHARIDE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 1A6; OPN 305; OPN 401; PATTERN RECOGNITION RECEPTOR; PEPTIDE; QUINAZOLINE DERIVATIVE; RESATORVID; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 3; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 5; TOLL LIKE RECEPTOR 6; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 9; UNCLASSIFIED DRUG;

ADAPTATION; COLITIS; DRUG INDICATION; DRUG TARGETING; ENTERITIS; HEART FAILURE; HOMEOSTASIS; HUMAN; INFLAMMATION; INNATE IMMUNITY; ISCHEMIC CARDIOMYOPATHY; NONHUMAN; OPIATE ADDICTION; PAIN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; RHEUMATOID ARTHRITIS; SEPSIS; SIGNAL TRANSDUCTION; STRESS; SYSTEMIC LUPUS ERYTHEMATOSUS; TISSUE INJURY; TISSUE REACTION;

ANIMALS; HEART FAILURE; HUMANS; IMMUNITY, INNATE; MOLECULAR TARGETED THERAPY; MYOCARDIUM; SIGNAL TRANSDUCTION; TOLL-LIKE RECEPTORS; TRANSLATIONAL MEDICAL RESEARCH; VENTRICULAR REMODELING;

EID: 80052795438     PISSN: 00222828     EISSN: 10958584     Source Type: Journal    
DOI: 10.1016/j.yjmcc.2010.11.003     Document Type: Review

References (40)

1. Janeway C.A., Medzhitov R. Introduction: the role of innate immunity in the adaptive immune response. Semin Immunol 1998, 10:349-350.
2. Bianchi M.E. DAMPs, PAMPs and alarmins: all we need to know about danger. J Leukoc Biol 2007, 81:1-5.
3. Gallucci S., Matzinger P. Danger signals: SOS to the immune system. Curr Opin Immunol 2001, 13:114-119.
4. Cowan D.B., Poutias D.N., del Nido P.J., McGowan F.X. CD14-independent activation of cardiomyocyte signal transduction by bacterial endotoxin. Am J Physiol Heart Circ Physiol 2000, 279:H619-H629.
5. Boyd J.H., Mathur S., Wang Y., Bateman R.M., Walley K.R. Toll-like receptor stimulation in cardiomyoctes decreases contractility and initiates an NF-kappaB dependent inflammatory response. Cardiovasc Res 2006, 72:384-393.
6. Frantz S., Kelly R.A., Bourcier T. Role of TLR-2 in the activation of nuclear factor-kappa B by oxidative stress in cardiac myocytes. J Biol Chem 2001, 276:5197-5203.
7. Hennessy E.J., Parker A.E., O'Neill L.A. Targeting Toll-like receptors: emerging therapeutics?. Nat Rev Drug Discov 2010, 9:293-307.
8. Frantz S., Kobzik L., Kim Y.D., Fukazawa R., Medzhitov R., Lee R.T., et al. Toll4 (TLR4) expression in cardiac myocytes in normal and failing myocardium. J Clin Invest 1999, 104:271-280.
9. Birks E.J., Felkin L.E., Banner N.R., Khaghani A., Barton P.J., Yacoub M.H. Increased toll-like receptor 4 in the myocardium of patients requiring left ventricular assist devices. J Heart Lung Transplant 2004, 23:228-235.
10. Frantz S., Ertl G., Bauersachs J. Mechanisms of disease: Toll-like receptors in cardiovascular disease. Nat Clin Pract Cardiovasc Med 2007, 4:444-454.
11. Satoh M., Shimoda Y., Akatsu T., Ishikawa Y., Minami Y., Nakamura M. Elevated circulating levels of heat shock protein 70 are related to systemic inflammatory reaction through monocyte Toll signal in patients with heart failure after acute myocardial infarction. Eur J Heart Fail 2006, 8:810-815.
12. Kim S.C., Stice J.P., Chen L., Jung J.S., Gupta S., Wang Y., et al. Extracellular heat shock protein 60, cardiac myocytes, and apoptosis. Circ Res 2009, 105:1186-1195.
13. Okamura Y., Watari M., Jerud E.S., Young D.W., Ishizaka S.T., Rose J., et al. The EDA domain of fibronectin activates toll-like receptor 4. J Biol Chem 2001, 276:10229-10233.
14. Mann D.L. Tumor necrosis factor and viral myocarditis: the fine line between innate and inappropriate immune responses in the heart. Circulation 2001, 103:626-629.
15. Chao W. Toll-like receptor signaling: a critical modulator of cell survival and ischemic injury in the heart. Am J Physiol Heart Circ Physiol 2009, 296:H1-H12.
16. Brown J.M., Grosso M.A., Terada L.S., Whitman G.J.R., Banerjee A., White C.W., et al. Endotoxin pretreatment increases endogenous myocardial catalase activity and decreases ischemia-reperfusion injury of isolated rat hearts. Proc Natl Acad Sci U S A 1989, 86:2516-2520.
17. Zhu X., Zhao H., Graveline A.R., Buys E.S., Schmidt U., Bloch K.D., et al. MyD88 and NOS2 are essential for toll-like receptor 4-mediated survival effect in cardiomyocytes. Am J Physiol Heart Circ Physiol 2006, 291:H1900-H1909.
18. Dong J.W., Vallejo J.G., Tzeng H.P., Thomas J.A., Mann D.L. Innate immunity mediates myocardial preconditioning through Toll-like receptor 2 and TIRAP-dependent signaling pathways. Am J Physiol Heart Circ Physiol 2010, 298:H1079-H1087.
19. Gross E.R., Hsu A.K., Gross G.J. Opioid-induced cardioprotection occurs via glycogen synthase kinase beta inhibition during reperfusion in intact rat hearts. Circ Res 2004, 94:960-966.
20. Chong A.J., Shimamoto A., Hampton C.R., Takayama H., Spring D.J., Rothnie C.L., et al. Toll-like receptor 4 mediates ischemia/reperfusion injury of the heart. J Thorac Cardiovasc Surg 2004, 128:170-179.
21. Kim S.C., Ghanem A., Stapel H., Tiemann K., Knuefermann P., Hoeft A., et al. Toll-like receptor 4 deficiency: smaller infarcts, but no gain in function. BMC Physiol 2007, 7:5.
22. Oyama J., Blais C., Liu X., Pu M., Kobzik L., Kelly R.A., et al. Reduced myocardial ischemia-reperfusion injury in toll-like receptor 4-deficient mice. Circulation 2004, 109:784-789.
23. Favre J., Musette P., Douin-Echinard V., Laude K., Henry J.P., Arnal J.F., et al. Toll-like receptors 2-deficient mice are protected against postischemic coronary endothelial dysfunction. Arterioscler Thromb Vasc Biol 2007, 27:1064-1071.
24. Feng Y., Zhao H., Xu X., Buys E.S., Raher M.J., Bopassa J.C., et al. Innate immune adaptor MyD88 mediates neutrophil recruitment and myocardial injury after ischemia-reperfusion in mice. Am J Physiol Heart Circ Physiol 2008, 295:H1311-H1318.
25. Shimamoto A., Chong A.J., Yada M., Shomura S., Takayama H., Fleisig A.J., et al. Inhibition of Toll-like receptor 4 with eritoran attenuates myocardial ischemia-reperfusion injury. Circulation 2006, 114:I270-I274.
26. Shishido T., Nozaki N., Yamaguchi S., Shibata Y., Nitobe J., Miyamoto T., et al. Toll-like receptor-2 modulates ventricular remodeling after myocardial infarction. Circulation 2003, 108:2905-2910.
27. Riad A., Jager S., Sobirey M., Escher F., Yaulema-Riss A., Westermann D., et al. Toll-like receptor-4 modulates survival by induction of left ventricular remodeling after myocardial infarction in mice. J Immunol 2008, 180:6954-6961.
28. Tavener S.A., Long E.M., Robbins S.M., McRae K.M., Van Remmen H., Kubes P. Immune cell Toll-like receptor 4 is required for cardiac myocyte impairment during endotoxemia. Circ Res 2004, 95:700-707.
29. Ringner M. What is principal component analysis?. Nat Biotechnol 2008, 26:303-304.
30. Parrillo J.E., Cunnion R.E., Epstein S.E., Parker M.E., Suffredini A.F., Brenner M., et al. A prospective randomized controlled trial of prednisone for dilated cardiomyopathy. N Engl J Med 1989, 321:1061-1068.
31. Mann D.L., Topkara V.K., Evans S., Barger P.M. Innate immunity in the adult Mammalian heart: for whom the cell tolls. Trans Am Clin Climatol Assoc 2010, 121:34-50.
32. Frantz S., Fraccarollo D., Wagner H., Behr T.M., Jung P., Angermann C.E., et al. Sustained activation of nuclear factor kappa B and activator protein 1 in chronic heart failure. Cardiovasc Res 2003, 57:749-756.
33. Grabellus F., Levkau B., Sokoll A., Welp H., Schmid C., Deng M.C., et al. Reversible activation of nuclear factor-kappaB in human end-stage heart failure after left ventricular mechanical support. Cardiovasc Res 2002, 53:124-130.
34. Torre-Amione G., Kapadia S., Lee J., Bies R.D., Lebovitz R., Mann D.L. Expression and functional significance of tumor necrosis factor receptors in human myocardium. Circulation 1995, 92:1487-1493.
35. Mann D.L. Inflammatory mediators and the failing heart: past, present, and the foreseeable future. Circ Res 2002, 91:988-998.
36. Chang Y.C., Kao W.C., Wang W.Y., Wang W.Y., Yang R.B., Peck K. Identification and characterization of oligonucleotides that inhibit Toll-like receptor 2-associated immune responses. FASEB J 2009, 23:3078-3088.
37. Chung E.S., Packer M., Lo K.H., Fasanmade A.A., Willerson J.T. Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the Anti-TNF Therapy Against Congestive Heart failure (ATTACH) Trial. Circulation 2003, 107:3133-3140.
38. Mann D.L., McMurray J.J.V., Packer M., Swedberg K., Borer J.S., Colucci W.S., et al. Targeted anti-cytokine therapy in patients with chronic heart failure: results of the Randomized EtaNcercept Worldwide evALuation (RENEWAL). Circulation 2004, 109:1594-1602.
39. Heymans S., Hirsch E., Anker S.D., Aukrust P., Balligand J.L., Cohen-Tervaert J.W., et al. Inflammation as a therapeutic target in heart failure? A scientific statement from the Translational Research Committee of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail 2009, 11:119-129.
40. Timmers L., Sluijter J.P., Van Keulen J.K., Hoefer I.E., Nederhoff M.G., Goumans M.J., et al. Toll-like receptor 4 mediates maladaptive left ventricular remodeling and impairs cardiac function following myocardial infarction. Circ Res 2007, 102:257-264.